Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
1.095
-0.095 (-7.98%)
Mar 31, 2025, 2:26 PM EDT - Market open
Acumen Pharmaceuticals Stock Forecast
ABOS's stock price has decreased by -70.98% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Acumen Pharmaceuticals stock have an average target of 7.33, with a low estimate of 4.00 and a high estimate of 11. The average target predicts an increase of 569.41% from the current stock price of 1.10.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Acumen Pharmaceuticals stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $6 → $4 | Strong Buy | Maintains | $6 → $4 | +265.30% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $11 | Strong Buy | Maintains | $15 → $11 | +904.57% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,269.86% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,269.86% | Oct 3, 2024 |
| UBS | UBS | Strong Buy Maintains $14 → $6 | Strong Buy | Maintains | $14 → $6 | +447.95% | Aug 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.90
from -1.71
EPS Next Year
-1.84
from -1.90
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.63 | -1.89 | -2.06 | ||
| Avg | -1.90 | -1.84 | -2.00 | ||
| Low | -2.10 | -1.76 | -1.92 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.